Cardiovascular Systems Financial Statements ()
|
|
|
|
Report date
|
|
|
23.08.2019 |
20.08.2020 |
19.08.2021 |
31.12.2021 |
18.08.2022 |
|
09.02.2023 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
248.0 |
236.5 |
259.0 |
|
236.2 |
|
239.8 |
|
Operating Income, bln rub |
|
|
-0.825 |
-26.8 |
-11.9 |
|
-35.8 |
|
-38.6 |
|
EBITDA, bln rub |
? |
|
-0.825 |
-25.5 |
-10.7 |
|
-34.5 |
|
-35.6 |
|
Net profit, bln rub |
? |
|
-0.255 |
-27.2 |
-13.4 |
|
-36.9 |
|
-37.9 |
|
|
OCF, bln rub |
? |
|
10.2 |
-12.8 |
-0.884 |
|
-24.3 |
|
-29.2 |
|
CAPEX, bln rub |
? |
|
3.56 |
4.09 |
3.95 |
|
4.22 |
|
4.52 |
|
FCF, bln rub |
? |
|
6.65 |
-16.9 |
-4.84 |
|
-28.5 |
|
-33.7 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
|
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
201.2 |
214.6 |
209.8 |
|
208.6 |
|
212.2 |
|
Cost of production, bln rub |
|
|
47.7 |
48.8 |
61.1 |
|
63.4 |
|
66.2 |
|
R&D, bln rub |
|
|
33.5 |
43.4 |
41.1 |
|
36.7 |
|
36.4 |
|
Interest expenses, bln rub |
|
|
1.68 |
1.97 |
1.74 |
|
1.63 |
|
1.63 |
|
|
Assets, bln rub |
|
|
218.6 |
339.5 |
352.6 |
326.4 |
322.7 |
|
311.5 |
|
Net Assets, bln rub |
? |
|
147.9 |
268.8 |
271.0 |
259.5 |
249.5 |
|
239.4 |
|
Debt, bln rub |
|
|
21.0 |
20.8 |
20.6 |
0.000 |
20.3 |
|
20.1 |
|
Cash, bln rub |
|
|
122.7 |
232.2 |
207.0 |
176.5 |
159.8 |
|
132.0 |
|
Net debt, bln rub |
|
|
-101.7 |
-211.3 |
-186.4 |
-176.5 |
-139.5 |
|
-111.9 |
|
|
Ordinary share price, rub |
|
|
42.9 |
31.6 |
42.7 |
18.8 |
14.4 |
|
13.6 |
|
Number of ordinary shares, mln |
|
|
33.5 |
34.3 |
38.8 |
|
39.2 |
|
39.7 |
|
|
Market cap, bln rub |
|
|
1 440 |
1 081 |
1 656 |
0 |
563 |
|
540 |
|
EV, bln rub |
? |
|
1 338 |
870 |
1 470 |
-177 |
424 |
|
428 |
|
Book value, bln rub |
|
|
143 |
252 |
256 |
243 |
234 |
|
224 |
|
|
EPS, rub |
? |
|
-0.01 |
-0.79 |
-0.35 |
|
-0.94 |
|
-0.95 |
|
FCF/share, rub |
|
|
0.20 |
-0.49 |
-0.12 |
|
-0.73 |
|
-0.85 |
|
BV/share, rub |
|
|
4.26 |
7.36 |
6.58 |
|
5.96 |
|
5.66 |
|
|
EBITDA margin, % |
? |
|
-0.33% |
-10.8% |
-4.14% |
|
-14.6% |
|
-14.9% |
|
Net margin, % |
? |
|
-0.10% |
-11.5% |
-5.18% |
|
-15.6% |
|
-15.8% |
|
FCF yield, % |
? |
|
0.46% |
-1.56% |
-0.29% |
0.00% |
-5.06% |
|
-6.23% |
|
ROE, % |
? |
|
-0.17% |
-10.1% |
-4.95% |
0.00% |
-14.8% |
|
-15.8% |
|
ROA, % |
? |
|
-0.12% |
-8.02% |
-3.81% |
0.00% |
-11.4% |
|
-12.2% |
|
|
P/E |
? |
|
-5 646 |
-39.7 |
-123.4 |
|
-15.3 |
|
-14.3 |
|
P/FCF |
|
|
216.4 |
-64.2 |
-342.3 |
|
-19.8 |
|
-16.0 |
|
P/S |
? |
|
5.80 |
4.57 |
6.40 |
|
2.38 |
|
2.25 |
|
P/BV |
? |
|
10.1 |
4.29 |
6.48 |
0.00 |
2.41 |
|
2.41 |
|
EV/EBITDA |
? |
|
-1 622 |
-34.1 |
-137.1 |
|
-12.3 |
|
-12.0 |
|
Debt/EBITDA |
|
|
123.3 |
8.28 |
17.4 |
|
4.05 |
|
3.14 |
|
|
R&D/CAPEX, % |
|
|
941.3% |
1 061% |
1 038% |
|
870.1% |
|
805.4% |
|
|
CAPEX/Revenue, % |
|
|
1.43% |
1.73% |
1.53% |
|
1.79% |
|
1.88% |
|
| Cardiovascular Systems shareholders |
